114 related articles for article (PubMed ID: 1017201)
1. Intravaginal contraception with the synthetic progestin, R2323.
Akinla O; Lähteenmäki P; Jackanicz TM
Contraception; 1976 Dec; 14(6):671-8. PubMed ID: 1017201
[TBL] [Abstract][Full Text] [Related]
2. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
[TBL] [Abstract][Full Text] [Related]
4. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
[TBL] [Abstract][Full Text] [Related]
5. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.
Olsson SE; Odlind V
Contraception; 1990 Nov; 42(5):563-72. PubMed ID: 2272184
[TBL] [Abstract][Full Text] [Related]
6. Intravaginal contraception with the synthetic progestin, R2010.
Toivonen J
Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
[TBL] [Abstract][Full Text] [Related]
7. Intravaginal and intracervical devices for the delivery of fertility regulating agents.
J Steroid Biochem; 1979 Jul; 11(1B):461-7. PubMed ID: 491617
[TBL] [Abstract][Full Text] [Related]
8. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
[TBL] [Abstract][Full Text] [Related]
9. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
[TBL] [Abstract][Full Text] [Related]
10. Subdermal norethindrone pellets -- a method for contraception?
Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
[TBL] [Abstract][Full Text] [Related]
11. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
Niaraki MA; Moghissi KS; Borin K
Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
13. Ovulation inhibition by a new low-dose progestagen.
Viinikka L; Hirvonen E; Ylikorkala O; Nummi S; Virkkunen P; Ranta T; Alapiessa U; Vihko R
Contraception; 1977 Jul; 16(1):51-8. PubMed ID: 334460
[TBL] [Abstract][Full Text] [Related]
14. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
[TBL] [Abstract][Full Text] [Related]
15. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
17. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
18. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel.
Mishell DR; lumkin M; Jackanicz T
Contraception; 1975 Sep; 12(3):253-60. PubMed ID: 1164845
[TBL] [Abstract][Full Text] [Related]
19. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.
Haukkamaa M; Laurikka-Routti M; Heikinheimo O; Moo-Young A
Contraception; 1992 Jan; 45(1):49-55. PubMed ID: 1591921
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]